ARA-290, also known as Cibinetide, is a novel peptide that represents a breakthrough in separating the tissue-protective properties of erythropoietin from its blood cell-stimulating effects. Developed by Araim Pharmaceuticals, the peptide is an 11-amino acid linear sequence derived from the helix B surface of EPO. It selectively activates the innate repair receptor (IRR) — a heterodimer of the EPO receptor and the beta common receptor (CD131) — which is expressed on damaged or stressed tissues. This selectivity means ARA-290 promotes healing and reduces inflammation without the dangerous side effects of EPO such as blood thickening and tumor growth. Phase 2 clinical trials have been completed for sarcoidosis-related neuropathy and diabetic neuropathy, showing improvements in nerve fiber density and neuropathic symptoms. The peptide has also shown promise for chronic wound healing and metabolic syndrome.
Key Data
Mechanism of Action
ARA-290 binds to the innate repair receptor (IRR), a heterodimer of EPO receptor and CD131/βc receptor, triggering anti-inflammatory and tissue-protective signaling cascades including JAK2/STAT5, PI3K/Akt, and NF-κB suppression, without stimulating red blood cell production.
Reported Benefits
All information is presented for Research Use Only (RUO). Not medical advice.